Abstract
Background: Castrate-resistant prostate cancer (CRPC) is challenging to treat with the Androgen Receptor (AR) still the main target and key player of resistance. Understanding the mechanisms of AR interaction with co-factors will identify new therapeutics not susceptible to AR resistance mechanisms. We identified Serum Response Factor (SRF) as a lead target in an in vitro model of CRPC and showed that SRF expression in tissues of CRPC patients was associated with shorter survival. Here we tested SRF-inhibition in vitro and in vivo to assess SRF as a potential target in CRPC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
